Accuray (ARAY)
(Delayed Data from NSDQ)
$1.62 USD
+0.08 (5.19%)
Updated May 3, 2024 04:00 PM ET
After-Market: $1.62 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value F Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.62 USD
+0.08 (5.19%)
Updated May 3, 2024 04:00 PM ET
After-Market: $1.62 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
C Value F Growth C Momentum D VGM
Zacks News
3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.
BeyondSpring Inc. (BYSI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
BeyondSpring Inc. (BYSI) delivered earnings and revenue surprises of 18.97% and 0.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Is Accuray (ARAY) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Accuray (ARAY) and Assertio (ASRT) have performed compared to their sector so far this year.
Accuray's (ARAY) CyberKnife System Gets Shonin Approval
by Zacks Equity Research
Accuray's (ARAY) CyberKnife System can now be marketed in Japan post the Shonin approval.
Zacks Industry Outlook Highlights: Thermo Fisher Scientific, STERIS and Accuray
by Zacks Equity Research
Zacks Industry Outlook Highlights: Thermo Fisher Scientific, STERIS and Accuray
3 Top Medical Instruments Stocks to Counter Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on COVID-support business gains. TMO, STE and ARAY are set to gain the most. Yet, demand for base business is on the decline with the new COVID variant disrupting the trend.
Accuray (ARAY) Down 15.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Reasons to Add Accuray (ARAY) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its slew of software upgrades.
After Golden Cross, Accuray (ARAY)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Earnings Estimates Rising for Accuray (ARAY): Will It Gain?
by Zacks Equity Research
Accuray (ARAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Here's What Could Help Accuray (ARAY) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Accuray (ARAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Accuray (ARAY) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Accuray (ARAY) registers growth in both Service and Product revenues during fiscal Q1.
Accuray (ARAY), C-RAD Ink Deal to Enhance Breast Cancer Treatment
by Zacks Equity Research
Accuray's (ARAY) latest agreement is likely to improve breast cancer treatment.
Accuray's (ARAY) Radiotherapy Technologies Adopted by Unicancer
by Zacks Equity Research
Accuray's (ARAY) proprietary radiotherapy technologies get selected by Unicancer, which is the largest network of comprehensive cancer centers in Europe.
Accuray's (ARAY) CyberKnife Favored For Prostate Cancer Treatment
by Zacks Equity Research
Per the PACE trial data, patients treated with Accuray's (ARAY) CyberKnife SBRT are likely to experience lesser bladder-related side effects unlike conventional linear accelerator.
Why Is Accuray (ARAY) Down 3.4% Since Last Earnings Report?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Accuray (ARAY) Posts In-Line Q4 Earnings, Beats on Revenues
by Zacks Equity Research
Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q4.
Accuray (ARAY) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of 0.00% and 9.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Accuray (ARAY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Accuray (ARAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Accuray's (ARAY) CyberKnife Gets Support From RayStation TPS
by Zacks Equity Research
Accuray (ARAY) introduces RayStation treatment planning support for CyberKnife Radiotherapy System and other radiation therapy devices.
Accuray (ARAY) Expands Commercialization of CE-Marked ClearRT
by Zacks Equity Research
Accuray's (ARAY) ClearRT imaging capability, which is now widely available following receipt of the CE Mark, offers better precision and accuracy in radiation therapy.
Accuray (ARAY) Down 13.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its slew of regulatory approvals and strength in its TomoTherapy platform.
New Strong Sell Stocks for April 30th
by Zacks Equity Research
ARAY, EBS, FARM, SHLX, and TPB have been added to the Zacks Rank #5 (Strong Sell) List on April 30, 2021
Accuray (ARAY) Posts Breakeven Q3 Earnings, Beats on Revenues
by Zacks Equity Research
Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q3.